More Neurotech International Ltd. news
Neurotech International Ltd.ASX: NTI

Extension to Voluntary Suspension

Jul 7, 2022 at 12:23 AM EDT · Issued by Neurotech International Ltd.

Filed with ASX · Jul 7, 2022 at 12:23 AM EDT

On 6ix: 6ix.com/news/extension-to-voluntary-suspension

Neurotech International Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Neurotech International Ltd. on 6ix

In the deck

  • Neurotech International — Investor Presentation (July 2022)18 slidesJul 8, 2022

Story so far

  • Voluntary SuspensionNov 27, 2020

Earlier from Neurotech International

  • Suspension from Official QuotationJul 6, 2022
  • Preclinical Success with Targeted Combination TherapiesJun 9, 2022
  • Successful Landmark Study in Paediatric ASDApr 4, 2022
  • Notification regarding unquoted securities - NTIMar 10, 2022
  • Neurotech International: Proposed issue of securities - NTIMar 3, 2022

Later from Neurotech International

  • Breakthrough results with NTI164 in paediatric asdJul 7, 2022
  • Reinstatement to Official QuotationJul 7, 2022
  • Q&A on NTI164 Breakthrough Clinical Trial Results in ASDJul 21, 2022
  • Executive ChangeSep 1, 2022
  • New Phase I/II Clinical Trial in Children with PANDAS/PANSOct 16, 2022
All Neurotech International news releases↗

Follow Neurotech International into a list and get an email when it puts out news.

Follow Neurotech International
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer